The cytokine cachectin/tumor necrosis factor (cachectin/TNF) plays a pivotal role in the pathophysiologic consequences of severe infection, and is a mediator of fatal bacteremic shock (reviewed in references 1, 2). Infusions ofrecombinant cachetin/TNF induce cardiovascular shock, hemorrhagic necrosis in tissues, and metabolic derangements similar to both experimental endotoxemia and clinical septic shock (3, 4) . Anti-cachectin/TNF antibodies protect mice (5) and rabbits (6) from otherwise lethal endotoxemia, and prevent the development of lethal septic shock syndrome during overwhelming experimental bacteremia in baboons (7) . Moreover, high concentrations of circulating cachectin/TNF correlate with lethal outcome in critically ill patients with meningococcal infection (8) , infectious purpura (9) , or burn injuryassociated septicemia (10) .
Two other cytokines, IL-1 and IL-6, have also been implicated in the pathophysiology ofinjury and infection (11) (12) (13) . IL-1 and IL-6 can be detected in the circulation of patients with active infection or endotoxemia (14) (15) (16) , and administration of IL-1 or IL-6 induces some of the characteristic physiological derangements associated with injury (17, 18) , including fever and acute-phase protein responses. The recent availability of sensitive and specific assays for IL-1 and IL-6 prompted us to measure the concentrations of these cytokines in stored plasma samples obtained in a previously reported series of lethal, experimental bacteremic challenges in baboons (7) . The current report demonstrates that gram-negative bacteremia induces rapid and marked increases in circulating IL-10 and IL-6. Moreover, passive immunization against cachectin/TNF attenuates the appearance ofIL-10 and IL-6, suggesting that cachectin/TNF is an essential stimulus for the release ofthese other cytokines during septic shock syndrome .
Materials and Methods
Experimental Protocol. The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the New York Hospital-Cornell Medical Center (NYH-CMC) . Female Papio anubis baboons (Charles River Primate Center, Port Jefferson, NY), free of infections and parasites, were housed in the animal care facility of the NYH-CMC . After a 12-h overnight fast, general anesthesia (sodium pentobarbital) was administered to the animals and maintained throughout the study period as previously described (7) .
All animals received an intra-aortic infusion of Escherichia coli 086 :B7 (1 .2 t 0 .3 x 10 1 ' live bacteria/kg body weight) over 30 min (19) . Individual baboons were randomized to one of three pretreatment groups : (a) animals receiving anti-cachectin/TNF antibodies (10 mg/kg) 1 hour before the bacterial infusion (Ab -1 h), n = 3 ; (b) animals receiving anti-cachectin/TNF antibodies (10 mg/kg) 2 h before the bacterial infusion (Ab -2 h), n = 3 ; and (c) control animals receiving saline infusions 1 h (n = 3) or 2 h (n = 3) before bacterial infusion. Arterial blood samples collected before and periodically for 8 h after bacterial challenge were assayed for cytokine levels and metabolic substrate concentrations . Plasma samples had been collected in heparinized tubes, centrifuged at 4 0 C, frozen immediately, and stored at -70'C until analysis .
Cachectin/TNFAntibody. Anti-cachectin/TNF mAbs were prepared as previously described (7) . F(ab')2 fragments were prepared by pepsin digestion of IgG (20), and purified by Mono Q(Pharmacia Fine Chemicals, Piscataway, NJ) column chromatography. Anti-cachectin/TNF antibodies at a concentration of 10 Pg/ml neutralized at least 50 ng/ml of recombinant human cachectin/TNF (101 U/mg) as assayed by L929 cell cytotoxicity assay (21) . Antibodies were diluted in 0 .9 17o saline and infused over a period of 30 min . The LPS content of the antibody preparation was <0 .25 ng/mg as assayed by the Limulus amebocyte lysate test .
IL-I Assay. Concentrations of IL-la and IL-lei in thawed plasma samples were assayed by two-site ELISA using mAbs specific for each protein (22) . The lower limit for detecting IL-1a is 36 pg/ml while that for IL-10 is 15 pg/ml . Baboon plasma does not inhibit the detection of exogenously added IL-1 in either assay.
IL-6Assay. IL-6 activity in plasma samples was measured by a B.9 hybridoma proliferation assay (23) . Briefly, serial dilutions of thawed plasma were incubated in triplicate with 2,000 B .9 cells for 84 h in 96-well microtiter plates . MTT (3-[4,5-dimethyl-thiazol-2-yl[2,5-diphenyltetrazolium bromide) (300 ug/ml) was added ; 3 h later the supernatant was removed and the cells were lysed with isopropanol-0 .004 N HCI . Cell proliferation was estimated colorimetrically in an ELISA plate reader (570, 690 nm) . One B .9 hybridoma growth unit was defined as the quantity of diluted plasma required to produce one-half maximal proliferation. Values for each sample were calculated by interpolation from three or four dilutions . Recombinant human cachetin/TNF and recombinant human IL-1 /3 have no proliferative effects in this assay. B .9 cell proliferation was not affected by as much as 10 wg/ml cachectin/TNF antibody in vitro. Inhibition by antiserum specific for human IL-6 verified specificity of this assay. The lower limit for detecting IL-6 by this assay is 50 U/ml . Metabolic Parameters. Plasma glucose concentrations were determined using an automated glucose analyzer (No . 23A ; Yellow Springs Instrument Co., Yellow Springs, Ohio) using the glucose oxidase reaction (24) . Plasma triglyceride concentrations were determined enzymatically (25) .
Statistical Analysis. All data are expressed as means t SEM . Two-way ANOVA and Newman-Kuels' tests were used in statistical analysis .
Results and Discussion
We have previously reported that the appearance of circulating cachectin/TNF in this primate model of septic shock is monophasic, peaking 1 .5 h after bacterial challenge (7) . The results of the current report demonstrate that two other cytokines, IL-10 and IL-6 also exhibit distinct and reproducible patterns of appearance during infection . Circulating IL-1/3, appearing slightly later than cachectin/TNF, was detectable by 2 h and peaked 3 h after the bacterial infusion (Fig . 1) . Circulating IL-6, appearing even later, was detectable within 3 h, and continued to rise throughout the 8-h study period (Fig . 2) .
In cultured macrophages and other cells, and in experimental animals, exposure to recombinant cachectin/TNF induces the biosynthesis of IL-1 and IL-6 ( . Circulating IL-6 levels during experimental bacteremia. Assay for IL-6 was performed on plasma obtained before (t = 0) and after E. coli infusions. Experimental animals were immunized against cachectin/TNF as described in Fig. 1. 26 ), and these factors have been implicated as secondary mediators of the pathophysiological effects of cachectin/TNF The present data indicate that during overwhelming infection, cachectin/TNF secretion preceded the production of IL-1S, and IL-6, and was a necessary stimulus for their release in vivo. Pretreatment with anti-cachectin/TNF antibodies significantly attenuated the circulating IL-10 response (p < 0.006) (Fig . 1) . Comparisons between peak IL-10 levels were particularly noteworthy (control : 2 .5 t 1.1 ng/ml; Ab (-1 h) : 1.4 t 0.5 ; Ab (-2 h) : 0 .3 t 0.2). Pretreatment with anti-cachectin/TNF antibodies also attenuated the IL-6 response to bacterial challenge (p < 0.004) (t = 8; control: 17 t 6 x 103 U/ml ; Ab (-1 h) : 6 t 6 x 103; Ab (-2 h) : 0.9 t 0.8 x 103) (Fig . 2) . Considering that bacterial LPS is itself a potent stimulus for IL-1 and IL-6 release in vitro (12, 13) , the observation that specific neutralization of cachectin/TNF significantly reduced appearance of IL-10 and IL-6 during overwhelming gram-negative bacteremia is striking.
No detectable IL-la was found in the circulation at any time point in any group despite the production of large quantities of IL-1(3. This is consistent with the observation that IL-10 is the predominate form of IL-1 produced by activated monocytes (27) . Since IL-1 and cachectin/TNF can induce the biosynthesis of IL-6, and the peak IL-1 level in the circulation precedes that of IL-6, it cannot be determined from the present study whether the attenuation of IL-6 is a direct or indirect effect of neutralizing cachectin/TNF Peak IL-6 levels correlate well with peak IL-10 responses in the current experiment (r = 0.87, data not shown), so it is possible that the reduced appearance of IL-6 was due in part to reduction of the earlier IL-1 response . Further studies with antibodies against IL-10 may resolve the question .
The overwhelming dose of live E. coli used in the current experiment caused a rapidly fatal syndrome in nonimmunized control animals that is likely attributable to tissue effects of cachectin/TNF Previously we reported that the earlier (-2 h) antibody treatment was more effective in preventing septic shock and mortality (7) . We now report that anti-cachectin/TNF antibodies given 2 h before bacterial challenge are significantly more effective in attenuating IL-10 and IL-6 appearance than antibodies administered only 1 h before E. coli . 2-h pretreatment was also more effective in reducing hypoglycemia and hypertriglyceridemia, which are characteristic metabolic sequelae of severe infections (Fig . 3) . Improved biologic outcome might well reflect superior tissue distribution and penetration with earlier antibody administration. Inability to completely prevent mortality, cytokine production, and metabolic derangements in the -1 h group might be attributed to incomplete neutralization of the large amounts of cachectin/TNF produced and acting in tissues in response to this overwhelming bacteremia. With less severe bacteremic challenge, improved survival and hemodynamic stability are observed when anti-cachectin/TNF antibodies are administered even 30 min after infusion oflesser quantities of bacteria (28) .
That cachectin/TNF elicits IL-1/3 and IL-6 release in infection further emphasizes the pivotal role of cachectin/TNF as a mediator of septicemia and septic shock syndrome . The lethality of cachectin/TNF is synergistically enhanced by even low concentrations of IL-1 (29) , so that stimulation of IL-1 biosynthesis by cachectin/TNF serves to amplify cachectin/TNFmediated shock and tissue injury. Further studies are necessary to determine the precise molecular and cellular mechanisms of cachectin/TNFmediated cytokine release. The current data nevertheless demonstrate that cachectin/TNF is a major determinant in the complex pathogenesis of 0 8 BL 8
OControl "Ab(-th) AAb(-2h) FIGURE 3 . Anti-cachectin/TNF antibodies prevent the hypoglycemia and hypertriglyceridemia of bacteremia. Arterial glucose and triglyceride levels were measured at baseline (BL, before bacterial infusion) and 8 h after E. coli . 'p < 0.05 vs . t = 0, ' p < 0.05 vs . control .
septic shock syndrome, not only through its direct toxicity, but also as a proximal mediator capable of inducing a cascade of other humoral factors .
Summary
Cytokines secreted in response to invading micro-organisms are important mediators ofdetrimental hemodynamic and metabolic changes in the host. To test whether cachectin/TNF plays a role in triggering release of other cytokines in the setting of infection, anesthetized baboons were passively immunized against systemic cachectin/TNF before infusion of a LDtoo dose of live Escherichia coli. Bacteremia led to significant increases in circulating levels of cachectin/TNF, IL-10, and IL-6. Although bacterial endotoxin/lipopolysaccharide is a potent stimulus for the synthesis and release of IL-1 and IL-6 in vitro, specific neutralization of cachectin/TNF in vivo with mAb pretreatment significantly attenuated both the IL-10 and the IL-6 responses despite fulminant overwhelming bacteremia. These data suggest that cachectin/TNF is essential for the initiation or amplification of IL-1 and IL-6 release during lethal gram-negative septic shock syndrome.
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